Novel norcassane-type diterpene from the seed kernels of Caesalpinia crista

Tetrahedron Letters

Volumn 44, Issue 36, 2003, Pages 6879-6882

  Banskota, Arjun H ^a   Attamimi, Faisal ^b   Usia, Tepy ^a   Linn, Thein Zaw ^a   Tezuka, Yasuhiro ^a   Kalauni, Surya K ^a   Kadota, Shigetoshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HASANUDDIN UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CAESALPINIA CRISTA EXTRACT; CARBON; DITERPENE; NORCAESALPININ A; NORCAESALPININ B; NORCAESALPININ C; PLANT EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; CAESALPINIA CRISTA; DRUG ISOLATION; DRUG STRUCTURE; MEDICINAL PLANT; SEED KERNEL; SPECTROSCOPY; STRUCTURE ANALYSIS;

CAESALPINIA; CAESALPINIA CRISTA;

EID: 0042159803     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(03)01722-2     Document Type: Article

References (16)

1. P. T. Eisai Indonesia. Medicinal Herb Index in Indonesia, 1st ed.; 1986; pp. 140.
2. 2 extract and% suppression of the parasitemia was calculated on the 4th day using the formula: [(average% of parasitemia in control-average% of parasitemia in treated mice)/average% of parasitemia in control]×100. The suppression of parasitemia at 10, 5 and 1 mg/kg doses were 98.6, 95.5 and 73.2%, respectively. The parasitemia level of the control group was 19.8% at the same time interval and considered to be 100% parasitemia.
3. Kim H.-S., Miyake H., Arai M., Wataya Y. Parasito. Int. 47:1998;59-67.
4. Gumede B., Folb P., Ryffel B. Parasito. Int. 52:2003;53-59.
5. Balmain A., Bjamer K., Connolly J.D., Ferguson G. Tetrahedron Lett. 49:1967;5027-5031.
6. Jiang R.-W., But P.P.H., Ma S.-C., Mak T.C.W. Phytochemistry. 57:2001;517-521.
7. Kitagawa I., Simanjuntak P., Mahmud T., Kobayashi M., Fujii S., Uji T., Shibuya H. Chem. Pharm. Bull. 44:1996;1157-1161.
8. Pascoe K.O., Burke B.A., Chan W.R. J. Nat. Prod. 49:1986;913-915.
9. Linn, T. Z.; Attamimi, F.; Usia, T.; Banskota, A. H.; Tezuka, Y.; Kadota, S. Abstract Book, 123rd annual meeting of the Pharmaceutical Society of Japan; March 27-29, 2003, Nagasaki, Japan; Abstract 27[P1]I-219.
10. +, 419.2070].
11. Barry J., Kagan H.-B., Snatzke G. Tetrahedron. 27:1971;4737-4748.
12. Snatzke G. Tetrahedron. 21:1965;413-419.
13. +, 419.2070].
14. +, 419.2070].
15. 7 infected erythrocytes, collected from donor mice, were inoculated intravenously in the tail vain of mice. The test compound 1 and artemisinin suspended in 0.5% CMC (0.5 ml) were given per oral at doses of 10, 1 and 0.1 mg/kg daily (five mice per group), the first administration was made 2 h after parasite inoculation (designated as day 0). At day 6 the parasitemia levels of control group treated only with 0.5% CMC became 18.2% and the parasitemia level of compound 1 and artemisinin treated groups and suppression of parasitemia were calculated using the same equation mention above.
16. Murakami N., Sugimoto M., Kawanishi M., Tamura S., Kim H.-S., Begum K., Wataya Y., Kobayashi M. J. Med. Chem. 46:2003;638-641.